(1 - 11 von 13
)
Naveed Shams is CEO of Santen US subsidiary
www.biospectrumasia.com
Santen Pharma appointed Dr Naveed Shams as president, CEO and chief scientific officer. Dr Shams has a medical degree from Dow Medical College, Pakistan; a PhD...
OPKO Health Appoints Industry Veteran Dr. Naveed Shams as Chief...
www.opko.com
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet patient needs and establish industry-leading positions in large, rapidly...
Sofinnova Partners: AAVantgarde Announces the Appointment of...
dgap.dgap.de
AAVantgarde Announces the Appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical Officer MILAN, ITALY / ACCESSWIRE / June 30, AAVantgarde Bio , a biotechnology start-up that is developing gene therapies for inherited retinal disorders based on Adeno-Associated Viral (AAV) vectors, announced the appointment of Naveed ...
News - Naveed Shams - The Pharma Letter
www.thepharmaletter.com
FDA calls for more evidence in IVT sirolimus The US Food and Drug Administration has issued a complete response letter (CRL) for the New Drug ...
Qura, Inc. Receives $1 Million Strategic Investment from
www.globenewswire.com
... an important measure that can help inform physicians about potential risk of disease severity or progression,” said Naveed Shams, MD, PhD, ...
Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM)...
eyewire.news
Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.
Ram Palanki Appointed VP- Strategic Marketing & Sales at Santen |...
www.ophthalmologyweb.com
Ram Palanki Appointed VP- Strategic Marketing & Sales at Santen
Santen Announces Topline Data for DE-128 (MicroShunt ...eyewire.news › articles › santen-announces-toplin...
eyewire.news
... procedure to produce predictable outcomes,” Naveed Shams, MD, PhD, Head of Santen's Global R&D, said in a company news release.
Santen initiates phase 3 trials of omidenepag isopropyl for glaucoma,...
www.healio.com
A pivotal phase 3 development program of omidenepag isopropyl for the treatment of glaucoma or ocular hypertension has been initiated by Santen Inc., the...
sortiert nach Relevanz / Datum